ASCO Early Release Offers Highlights, But The Best Is Yet To Come
This article was originally published in The Pink Sheet Daily
Executive Summary
Part one of “The Pink Sheet” DAILY’s review of roughly 5,000 abstracts released ahead of the American Society of Clinical Oncology annual meeting.
You may also be interested in...
Celgene Withdraws EU Filing For Revlimid After Second CHMP Refusal
Company counters setback by unveiling promising lenalidomide data from NHL, newly diagnosed multiple myeloma trials during ASCO.
Celgene Withdraws EU Filing For Revlimid After Second CHMP Refusal
Company counters setback by unveiling promising lenalidomide data from NHL, newly diagnosed multiple myeloma trials during ASCO.
ASCO Preview Highlights Study Of Alimta For First-Line NSCLC
Maintenance therapy with Lilly’s pemetrexed shows increase in progression-free survival in the only drug-related abstract in ASCO’s press call.